Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab
More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.
Authors
- Joseph J. Eron (ORCID: https://orcid.org/0000-0002-4938-0644)
- Marina Caskey (ORCID: https://orcid.org/0000-0003-1727-8693)
- Hailin Huang (ORCID: https://orcid.org/0000-0002-5012-9991)
- Laurie A. VanderVeen
- Gordon E Crofoot
- Megha Mehrotra (ORCID: https://orcid.org/0000-0003-1748-8690)
- Linda Gorgos
- Yanan Zheng (ORCID: https://orcid.org/0000-0003-3076-0003)
- Edwin DeJesus
- Sean E Collins (ORCID: https://orcid.org/0009-0002-9657-6874)
- Olayemi Osiyemi
- Paul Cook
- Cynthia Brinson
Institutions
- University of North Carolina at Chapel Hill (US)
- East Carolina University (US)
- School for Advanced Research (US)
- Triple O Medical Services (US)
- Clinical Research Organization (BD)
- Orlando Immunology Center (US)
- Gilead Sciences (United States) (US)
- Gilead Sciences (Australia) (AU)
- Texas A&M University – Central Texas (US)
- Rockefeller University (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1093/infdis/jiaf159
- Citations
- 5
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.98